Changes in Beneficial Ownership · 4
Faeth Therapeutics, Inc.
FTHNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-09152026_080937.xml
Filing details
- Report period
- 2026-09-11
- Issuer
- Faeth Therapeutics, Inc.
- Issuer CIK
- 0001829802
- Trading symbol
- FTH
Reporting owner 1
- Name
- Vousden Karen H
- Reporting owner CIK
- 0001723884
- Relationship
- Director
- Address
- C/O FAETH THERAPEUTICS, INC., 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 37.44 | 2026-09-11 | A · Form 4 | 25,000 | A | 0 | [F1] | 2036-09-10 | Common Stock | 25,000 | 25,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or September 11, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.↩ 1
Signature 1
- Signed
- /s/ Josiah Craver, Attorney-in-Fact
- Date
- 2026-09-15
Company context
Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph. D., together with scientific founders Lewis Cantley, Ph. D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph. D.; Scott Lowe, Ph. D.; and Greg Hannon, Ph. D. The Company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.faeththerapeutics.com and follow the Company on LinkedIn.
Current securities
Recent company filings
- S-8 filingNov 3, 2026
- Results of Operations and Financial ConditionNov 3, 2026
- 10-Q filingNov 3, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 27, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 17, 2026